Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient
Aardvark Therapeutics reports Phase 3 data for ARD-101 and prepares to meet with the FDA to discuss lower-dose testing.
Share
Why It Matters
Aardvark's medicine for a rare disease did not work well enough. The company will talk with doctors about testing a smaller dose instead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.